Publications by authors named "B Druker"
BCR-ABL1 compound mutations can lead to resistance to ABL1 inhibitors in chronic myeloid leukemia (CML), which could be targeted by combining the ATP-site inhibitor ponatinib and the allosteric inhibitor asciminib. Here, we report the clinical validation of this approach in a CML patient, providing a basis for combination therapy to overcome such resistance.
View Article and Find Full Text PDFArticle Synopsis
- The 2022 European LeukemiaNet (ELN) classification predicts outcomes for younger acute myeloid leukemia (AML) patients but was tested for those aged 60 and older receiving lower-intensity treatment (LIT), involving 595 patients with varying risk levels.
- Results showed that while ELN risk is predictive of overall survival, it fails to distinguish between favorable and intermediate risks, prompting further exploration into adverse-risk patients' molecular abnormalities.
- A new "Beat-AML" risk classification was developed, combining favorable and intermediate risks and integrating mutation scoring, leading to better survival predictions for older AML patients and aiding treatment decisions with clear risk group delineations.
Article Synopsis
- Acute myeloid leukemia (AML) is a challenging cancer to treat due to its complex genetic mutations, which often do not predict how well patients will respond to therapy.
- This study combines multiple data types (proteomic, transcriptomic, and drug sensitivity) from 210 AML patients to uncover new disease subtypes and their drug response patterns beyond just genetic mutations.
- The researchers created a model to predict drug responses tailored to these new subtypes, enhancing treatment strategies and potential drug combinations for AML patients.